“clinical-trials” Archives

in
Entry Author Date Location
Hunting For Pharma Deals, Ovid Bags Epilepsy Drug from Takeda 01/18/17 New York
Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay 01/13/17 National
CEO Kaye Details Insurance Battle As Sarepta Launches Duchenne Drug 01/10/17 Boston
Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug 01/06/17 National
RaNA Expands, Joins Messenger RNA Drug Race With Shire Deal 01/04/17 Boston
Inotek’s Glaucoma Drug Flunks in First Phase 3 Test, Shares Crumble 01/03/17 Boston
First Trial Underway, Jounce Preps IPO To Fund Immuno-Oncology Work 01/03/17 Boston
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More 12/23/16 National
14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) 12/22/16 National
14 For ’17: Key Clinical Data to Watch For Next Year (Part 1) 12/21/16 National
Akebia Gets $265M From Otsuka to Bankroll Anemia Drug Push 12/20/16 Boston
Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug 12/19/16 Boulder/Denver
After Setback, Ophthotech Restructures, Dials Down Eye Drug Studies 12/16/16 New York
After FDA Hold, Agios Quickly Scraps One Anemia Drug, Turns to Another 12/15/16 Boston
Ophthotech Eye Drug Fails Badly in Pivotal Test, Shares Crumble 12/12/16 New York
Amyloid Hypothesis Lives On—Solanezumab, Too, Despite “Siren Song” 12/09/16 Indiana
Houston Biotech Vapogenix Raises $8.2M for Phase 2 Trial 12/08/16 Texas
Voyager’s Gene Therapy for Parkinson’s Shows Promise in Small Study 12/07/16 Boston
ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More 12/06/16 National
Fresh Off ASH Data, Spark Teams With Selecta to Boost Gene Therapies 12/05/16 Boston
Bio Roundup: CAR-T Ups & Downs, Lilly’s Failure, Myeloma & More 12/02/16 National
In Year of CAR-T Trouble, Can Bluebird, Penn Make Headway in Myeloma? 11/30/16 Boston
Amicus Shares Fall On Another Bump in Rough Road To U.S. Fabry Nod 11/28/16 New York
Amyloid Hypothesis Takes a Hit As Lilly’s Alzheimer’s Drug Fails Again 11/23/16 Indiana
Acorda Leans on Parkinson’s Drugs After Post-Stroke Study Fails 11/21/16 New York
Regeneron: It’s Still Wait Until 2017 For Big Heart Drug Study 11/17/16 New York
Keeping Lead in Migraine Drug Race, Amgen Touts Data, Preps FDA Filing 11/16/16 San Francisco
With New Data, Medicines Co. Takes Long-Lasting Heart Drug to Phase 3 11/15/16 New York
Struggling UniQure Cuts Gene Therapies, Jobs, in Big Restructuring 11/15/16 Boston
Page 1 of 21 next page »